Theodore Alan Huizenga - 20 Dec 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: SVP, Chief Accounting Officer
Signature: /s/ Karah Parschauer, attorney-in-fact
Issuer symbol: RARE
Transactions as of: 20 Dec 2023
Net transactions value: +$63,000
Form type: 4
Filing time: 02 Jan 2024, 16:06:43 UTC
Previous filing: 29 Sep 2023
Next filing: 05 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Award	$0	+1,000	+4.2%	$0.000000	24,614	20 Dec 2023	Direct	F1
transaction	RARE	Common Stock	Options Exercise	$63,000	+3,000	+12%	$21.00	27,892	02 Jan 2024	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RARE	Stock Option (Right to Buy)	Options Exercise	$0	-3,000	-100%	$0.000000^*	0	02 Jan 2024	Common Stock	3,000	$21.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
F2	Includes 278 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023.
F3	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F4	1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter.